In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 peptides · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Synthetic analog Survodutide | Synthetic analog Retatrutide | |
|---|---|---|---|
| Identity | |||
| Kind | Synthetic analog | Synthetic analog | |
| Area | Weight and metabolic | Weight and metabolic | |
| Evidence | |||
| Amount of evidence | 172 | 380 | |
| Evidence level | Has results from studies in people | Has results from studies in people | |
| Safety | |||
| Safety results | 37 (37 in people) | 61 (61 in people) | |
| Status | |||
| Approval | |||
| Sport (WADA) | |||
| Registered trials | 35 · 10 active1 more mentions it but does not test it | 34 · 11 active | |
Shared outcomes
From the regulatory data of each peptide.
Its most advanced trial is in phase 3. The FDA, the EMA and the other sources we use show no approval (as of 9 Oct 2026).
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | Survodutide | Retatrutide |
|---|---|---|
| Body weightMetabolic and weight | 42384 | 987919 |
| Adverse events |
PepBank is a research reference. Talk to a doctor before you use any peptide.
Its most advanced trial is in phase 3. The FDA, the EMA and the other sources we use show no approval (as of 9 Oct 2026).
2424 |
3838 |
| Glycemic controlMetabolic and weight | 30237 | 32266 |
|---|
| Liver fat and liver functionLiver | 29281 | 20137 |
|---|
| Gastrointestinal adverse eventsGastrointestinal | 1212 | 1717 |
|---|
| LipidsCardiovascular | 22 | 271611 |
|---|
| Appetite and food intakeNervous system and cognition | 22 | 19136 |
|---|
| Receptor activity and mechanismPharmacology | 185112 | 24816 |
|---|
| Kidney functionKidney and urinary | 66 | 1495 |
|---|
| PharmacokineticsPharmacology | 33 | 66 |
|---|
| MortalityWhole body | 11 | 66 |
|---|
| Inflammation markersKidney and urinary | 11 | 14410 |
|---|
Each analog against its native parent, residue by residue. Substitutions, non-standard residues and modifications are marked. Calculated from the two sequences.
Survodutide differs from Glucagon at 9 positions.
What is different
Retatrutide differs from Gastric inhibitory polypeptide (GIP) at 15 positions and in 1 end segment.
What is different
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
Top 3 of 35 trials, ranked by phase, then posted results and enrollment: 2 ongoing · 1 completed · source ClinicalTrials.gov (opens in a new tab)
Boehringer Ingelheim5,531 participants20 Nov 2023 to 30 Jun 2026
Obesity
Boehringer Ingelheim1,800 participants14 Oct 2024 to est. 27 Dec 2031
Metabolic Dysfunction Associated Steatohepatitis (MASH) · Liver Fibrosis
Boehringer Ingelheim1,590 participants12 Nov 2024 to est. 5 Jun 2029
Metabolic Dysfunction Associated Steatohepatitis
1 more mentions it but does not test it. They only measure it or name it in their text.
Top 3 of 34 trials, ranked by phase, then posted results and enrollment: 2 ongoing · 1 completed · source ClinicalTrials.gov (opens in a new tab)
Eli Lilly and Company10,000 participants30 Apr 2024 to est. Feb 2029
Atherosclerotic Cardiovascular Disease (ASCVD) · Chronic Kidney Disease (CKD)
Eli Lilly and Company4,500 participants15 Oct 2025 to est. Aug 2032
Metabolic Dysfunction-Associated Steatotic Liver Disease
Eli Lilly and Company2,335 participants10 Jul 2023 to 30 Apr 2026
Obesity · Overweight · Osteoarthritis, Knee · Obstructive Sleep Apnea
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
| Outcome | Survodutide | Retatrutide |
|---|---|---|
| Body weightMetabolic and weightCompared as: value in the arm that got the peptide, in % | −12.2% Mean body weight change · survodutide 3.6 mg Placebo: −5.4% Dose studied: up to 3.6 mg once weekly76 weeksn not reported2026 | −23.7% Percent change in body weight · retatrutide 9 mg Placebo: −3.9% Dose studied: 9 mg80 weeksn not reported2026 |
| Gastrointestinal adverse eventsGastrointestinalCompared as: share of people in the arm that got the peptide, in % | 66% Nausea incidence Placebo: 23% Dose studied: 2.4, 4.8 or 6.0 mg once weekly48 weeksn = 2932024 | 14% Participants with nausea · retatrutide 4 mg Placebo: 8% |
−12.2%
Mean body weight change · survodutide 3.6 mg
Placebo: −5.4%
Dose studied: up to 3.6 mg once weekly76 weeksn not reported2026
−23.7%
Percent change in body weight · retatrutide 9 mg
Placebo: −3.9%
Dose studied: 9 mg80 weeksn not reported2026
The other peptides have no randomized result on the same measure, so these results cannot be set side by side.
| Outcome | Survodutide | Retatrutide |
|---|---|---|
| Glycemic controlMetabolic and weightCompared as: value in the arm that got the peptide, in % | No comparable result 17 randomized-trial results measure it in another way or another unit. | −1.69% HbA1c change · retatrutide 4 mg Dose studied: 4 mg once weekly40 weeksn not reported |
66%
Nausea incidence
Placebo: 23%
Dose studied: 2.4, 4.8 or 6.0 mg once weekly48 weeksn = 2932024
14%
Participants with nausea · retatrutide 4 mg
Placebo: 8%
Dose studied: 4 mgn = 5792026
| Liver fat and liver functionLiverCompared as: share of people in the arm that got the peptide, in % | 47% MASH improvement responders · survodutide 2.4 mg Placebo: 14% Dose studied: 2.4 mg once weekly48 weeksn not reported2024 | No comparable result 12 randomized-trial results measure it in another way or another unit. |
|---|
| PharmacokineticsPharmacologyCompared as: value in the arm that got the peptide, in days | No comparable result 1 randomized-trial result measure it in another way or another unit. | ≈ 6 days Half-life · LY3437943 Dose studied: 0.5 mg, 1.5 mg, 3 mg, 3/6 mg and 3/6/9/12 mg once weekly12 weeksn not reported2022 |
|---|
| Kidney functionKidney and urinaryCompared as: value in the arm that got the peptide, in % | No randomized trial result 6 results from other study designs. | −37% UACR difference vs placebo · retatrutide 12 mg, T2D, week 36 Dose studied: 12 mg36 weeksn not reported2025 |
|---|
| Adverse eventsMetabolic and weightCompared as: value in the arm that got the peptide, in % | No comparable result 8 randomized-trial results measure it in another way or another unit. | 63% Treatment-emergent adverse events · LY3437943 Placebo: 54% Dose studied: 0.5 mg, 1.5 mg, 3 mg, 3/6 mg and 3/6/9/12 mg once weekly12 weeksn = 722022 |
|---|
No comparable result
17 randomized-trial results measure it in another way or another unit.
−1.69%
HbA1c change · retatrutide 4 mg
Dose studied: 4 mg once weekly40 weeksn not reported2026
47%
MASH improvement responders · survodutide 2.4 mg
Placebo: 14%
Dose studied: 2.4 mg once weekly48 weeksn not reported2024
No comparable result
12 randomized-trial results measure it in another way or another unit.
No comparable result
1 randomized-trial result measure it in another way or another unit.
≈ 6 days
Half-life · LY3437943
Dose studied: 0.5 mg, 1.5 mg, 3 mg, 3/6 mg and 3/6/9/12 mg once weekly12 weeksn not reported2022
No randomized trial result
6 results from other study designs.
−37%
UACR difference vs placebo · retatrutide 12 mg, T2D, week 36
Dose studied: 12 mg36 weeksn not reported2025
No comparable result
8 randomized-trial results measure it in another way or another unit.
63%
Treatment-emergent adverse events · LY3437943
Placebo: 54%
Dose studied: 0.5 mg, 1.5 mg, 3 mg, 3/6 mg and 3/6/9/12 mg once weekly12 weeksn = 722022